Press Releases

New doctoral thesis strengthens PExA’s opportunities in lung cancer and other lung diseases

A new doctoral thesis from Lund University, entirely based on PExA’s technology for analysing exhaled particles from the lungs, strengthens the view of PExA as a platform for non-invasive biomarker analysis. The thesis shows how PExA-based breath samples can provide biologically relevant information across four different areas of lung disease: infection/COVID-19, lung transplantation, acute lung…

Read more

TV4 News highlights research where PExA’s technology is being used for future early detection of lung cancer

During Sunday, Swedish national broadcaster TV4 News featured research where PExA’s technology is being used in several of its national news broadcasts. The report focused on future possibilities for detecting lung diseases such as COPD and lung cancer at an earlier stage through analysis of exhaled air. In the feature, titled “New technology may detect…

Read more

PExA partner in Dutch precision medicine project within COPD and interstitial lung diseases

PExA has become an industrial partner in the Dutch research project COPD-PARASOL-ILD, which forms part of the national precision medicine initiative P4O2. The project aims to identify and validate biomarkers for improved diagnosis and treatment monitoring in chronic lung diseases such as COPD and interstitial lung disease (ILD).  Other partners in the project are amongst…

Read more

Additional funding strengthens a growing research environment in Örebro where PExA is used in multiple studies

PExA announces that the Company’s instrument and method are playing an increasingly clear role in the growing research environment at Örebro University and Region Örebro County, focused on occupational particle exposure and early biomarkers of lung effects.  Örebro University and Region Örebro County have been awarded SEK 2.4 million from Nyckelfonden 2026 for the RESPIMARK…

Read more